744-P: Dosing Patterns of Tirzepatide (TZP) in Patients with Type 2 Diabetes (T2D) from a Commercially Insured U.S. Population

Intro 56% on the 2nd and 23% on the 3rd fill. Median time to first escalation was 45 days; 33% escalated from 2.5 mg to 5 mg and 37% from 5 mg to 7.5 mg. Of the patients with no dose changes and ≥3 fills (n=2505), 57% stayed on the 5 mg dose and 26% of people on 2.5 mg. Conclusion: Real-world evidence suggests that most patients with T2D had at least one dose increase for TZP, with 5 mg being the most prescribed and retained dose in the first 6 months of treatment with TZP. Disclosure R. Mody: Employee; Eli Lilly and Company. K. Desai: Employee; Carelon Research. Stock/Shareholder; Anthem, Inc. C. Teng: Employee; Carelon Research. G. Reznor: None. G. Stockbower: None. M. Grabner: Employee; Carelon Research. Stock/Shareholder; Anthem, Inc. B.D. Benneyworth: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company.